Amikacin for treatment of infections in patients with malignant diseases.
Amikacin was evaluated in patients with malignant diseases during 134 episodes of identified infection, most of which were cases of pneumonia and septicemia. The overall rate of response of the identified infections was 63%. The majority of infections were caused by Escherichia coli, the Klebsiella-Enterobacter-Serratia group, and Pseudomonas aeruginosa. The response rate for infections caused by these organisms was 80%. Five of eight infections caused by organisms resistant to gentamicin responded to therapy with amikacin. Nephrotoxicity was observed in 13% of patients who had normal renal function initially.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000583:Amikacin / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D001772:Blood Cell Count; D004756:Enterobacteriaceae Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy; D005260:Female; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D009504:Neutrophils; D011552:Pseudomonas Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy
D007612:Kanamycin; D000583:Amikacin